ArticlePloS one2026
Effect of pharmacokinetically-relevant ivermectin concentrations on survivorship and fecundity of Anopheles coluzzii and Aedes aegypti in Burkina Faso: A laboratory experimental study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe control of vector-borne diseases is increasingly challenged by insecticide resistance widespread. Therefore, innovative vector control tools with alternative modes of action are urgently needed to support existing ones. Ivermectin (IVM), a broad-spectrum endectocide has been shown to exert lethal effects on mosquitoes, including Anopheles and Aedes species following blood meals taken from treated humans or livestock. In this study, we assessed the effect of IVM at concentrations equivalent to human plasma levels following mass drug administration (MDA), on the survival and fecundity of An. coluzzii and Ae. aegypti in Burkina Faso. The present study provides new insights into how IVM may impact differentially both malaria and arbovirus vectors, contributing to develop integrated strategies of vectors control.
methodsTwo laboratory experiments were conducted using 3-5-days old wild-derived female An. coluzzii and Ae. aegypti. Each experiment included four replicates per IVM concentration and was performed on separate dates. Mosquitoes were membrane fed with rabbit blood treated with five IVM concentrations (C = 112 ng/mL, C2 = 29 ng/mL, C3 = 15 ng/mL, C4 = 6.5 ng/mL, C5 = 2.5ng/mL), corresponding to the mean human plasma levels at 2, 4, 7, 14, and 28 days post-MDA with IVM at a dose of 3x300 µg/kg. A negative control with free-IVM (0.0 ng/mL) was also included. Mosquito mortalities were recorded daily for 7 days. Fecundity was measured by counting both laid and developed eggs (via ovary dissection).
resultsIVM significantly reduced the survival of An. coluzzii compared to the control group (p < 0.001), with the risk of death increasing from 4.2-fold at the lowest concentration (2.5 ng/mL) to 64.2-fold at the highest (112 ng/mL). In contrast, IVM had no significant effect on Ae. aegypti (p > 0.05), and the survival rate of control group did not differ from that of treatment groups. Additionally, for An. coluzzii, IVM significantly reduced both egg laying and egg development (p < 0.0001 and p < 0.001, respectively), whereas no significant impact on fecundity was observed in Ae. aegypti (all p > 0.80).
conclusionIVM concentrations typically achieved in human plasma during MDA campaigns were sufficient to significantly reduce both survival and fecundity of wild type An. coluzzii, but had no measurable effect on Ae. aegypti. These findings highlight the species-specific response to IVM and support its potential role in integrated vector control strategies targeting malaria vectors in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.